OTUD4 Knockout Raji Polyclonal Cells constitute a heterogeneous pool of Raji B lymphocytes engineered via CRISPR/Cas9-mediated disruption of the OTUD4 gene, yielding a loss-of-function model for functional deubiquitinase studies. This polyclonal knockout population, derived from the human Burkitt’s lymphoma cell line, retains the full genetic background of the parental Raji cells while exhibiting a spectrum of OTUD4 mutations across individual cells. The product is designed to enable robust investigation of OTUD4-dependent signaling events without the constraints of clonal selection, making it suitable for pooled screening and population-level analyses of ubiquitin-dependent regulatory mechanisms.
Raji cells are an Epstein-Barr virus (EBV)-positive B lymphocyte line originating from a patient with Burkitt’s lymphoma, a highly aggressive non-Hodgkin lymphoma. This cell line is a widely accepted model for studying B cell biology, lymphomagenesis, and host?Cpathogen interactions due to its well-characterized karyotype, rapid proliferation, and retention of key signaling pathways. The EBV latency III program expressed in Raji cells drives constitutive activation of NF-??B and other oncogenic cascades, providing a relevant context for examining how deubiquitinases like OTUD4 intersect with viral and cellular tumorigenic pathways.
OTUD4 encodes a member of the ovarian tumor (OTU) domain-containing deubiquitinase family that specifically cleaves K48-linked polyubiquitin chains, a modification typically targeting proteins for proteasomal degradation. Mechanistically, OTUD4 safeguards antiviral innate immunity by removing K48-linked ubiquitin from the cytosolic RNA sensor RIG-I, thereby preventing its degradation and sustaining downstream MAVS?CTBK1?CIRF3 signaling. In parallel, OTUD4 stabilizes Dishevelled (DVL) proteins, critical transducers of the Wnt/??-catenin pathway, by a similar deubiquitination mechanism. Furthermore, OTUD4 modulates NF-??B signaling through interactions with TRAF3 and TRAF6, influencing the phosphorylation and degradation of I??B?? and the nuclear translocation of p65. Thus, OTUD4 operates at the crossroads of RIG-I antiviral responses, Wnt signaling, and NF-??B-driven inflammatory gene expression, integrating signals from upstream activators such as type I interferons and IRF3.
In the Raji B-cell lymphoma background, OTUD4 disruption has significant implications for dissecting the interplay between viral oncogenesis, innate immunity, and dysregulated signaling networks. Constitutive NF-??B activity and EBV latency factors in Raji cells create a unique milieu where OTUD4??s deubiquitinase function may influence not only cell-intrinsic antiviral defenses but also pro-survival and proliferative pathways central to lymphoma maintenance. By abrogating OTUD4 expression, researchers can probe its role in restraining apoptotic signals, modulating cytokine production, and altering the stability of key signaling intermediates such as RIG-I and DVL2 under conditions mimicking the tumor microenvironment. This model is particularly valuable for evaluating whether OTUD4 acts as a tumor suppressor or an oncogenic facilitator in B-cell malignancies and for assessing its potential as a therapeutic target in lymphomas with aberrant ubiquitin-mediated regulation.
OTUD4 Knockout Raji Polyclonal Cells are well-suited for a range of experimental applications in deubiquitinase biology, immuno-oncology, and antiviral research. Typical assays include Western blotting and RT-qPCR for confirming target protein and transcript ablation, NF-??B luciferase reporter assays to measure pathway activity, and RIG-I signaling activation analyses following viral mimic stimulation. Co-immunoprecipitation protocols can be employed to assess ubiquitination status of OTUD4 substrates such as RIG-I and DVL proteins, while flow cytometry permits evaluation of apoptosis and proliferation. The model also supports functional genomics and drug target validation studies, especially for cancer immunotherapy strategies targeting the ubiquitin-proteasome system. For further information or custom inquiries, please contact Ascent Research.
